A phase 3 multicentre randomized double-blind placebo controlled study of rilotumumab (AMG 102) with epirubicin cisplatin and capecitabine (ECS) as first-line therapy in advanced MET-positive gastric

Project: Research

StatusFinished
Effective start/end date8/04/1330/11/14